AMBU Q2 2022/23 Results Investor Presentation

AMBU A/S reported Q2 2022/23 results with 4% organic revenue growth and 3.9% EBIT margin, driven by double-digit growth in Endoscopy Solutions offsetting declines in Anaesthesia and Patient Monitoring. The company noted underlying market improvement with elective procedure volumes approaching pre-Covid levels, though hospital staffing challenges persist.